News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
296,724 Results
Type
Article (15753)
Company Profile (262)
Press Release (280700)
Multimedia
Podcasts (127)
Webinars (13)
Section
Business (90826)
Career Advice (170)
Deals (13526)
Drug Delivery (69)
Drug Development (51102)
Employer Resources (32)
FDA (6011)
Job Trends (5224)
News (145934)
Policy (10090)
Tag
2025 Best Places to Work (13)
2026 Best Places to Work (19)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Standard (3)
40 Under 40 (4)
Academia (978)
Accelerated approval (39)
ADA (34)
Adcomms (16)
Allergies (128)
Alliances (21770)
ALS (204)
Alzheimer's disease (1263)
Antibody-drug conjugate (ADC) (582)
Approvals (6441)
Artificial intelligence (491)
ASCO (224)
Autoimmune disease (410)
Automation (20)
Bankruptcy (112)
Belgium (30)
Best Places to Work (4559)
BIO (56)
Biologics (71)
BIOSECURE Act (6)
Biosimilars (161)
BioSpace Insights (81)
Biotechnology (179)
Bispecific (54)
Bladder cancer (143)
Brain cancer (73)
Breast cancer (510)
Cancer (5048)
Cardiovascular disease (375)
Career advice (174)
Career pathing (15)
CAR-T (347)
CDC (11)
CDMO (127)
Celiac Disease (6)
Cell therapy (889)
Cervical cancer (31)
Clinical research (46642)
Collaboration (1779)
Commercialization (44)
Company closure (4)
Compensation (988)
Complete response letters (73)
COVID-19 (1156)
CRISPR (131)
CRO (4)
C-suite (1057)
Cystic fibrosis (132)
Data (7642)
Denatured (27)
Depression (134)
Dermatology (131)
Diabetes (404)
Diagnostics (1562)
Digital health (21)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (360)
Drug pricing (55)
Drug shortages (4)
Duchenne muscular dystrophy (344)
Earnings (33924)
Editorial (37)
Employer branding (4)
Employer resources (30)
ESMO (311)
Events (55586)
Executive appointments (804)
Eye disease (16)
FDA (8826)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (36)
Funding (1495)
Gene editing (264)
Generative AI (50)
Gene therapy (725)
GLP-1 (638)
Government (1217)
Grass and pollen (3)
Guidances (182)
Healthcare (6833)
Hematology (144)
HIV (40)
Huntington's disease (75)
Idiopathic pulmonary fibrosis (10)
IgA nephropathy (125)
Immunology and inflammation (291)
Immuno-oncology (123)
Indications (191)
Infectious disease (1338)
Inflammatory bowel disease (216)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (262)
Interviews (21)
IPO (7422)
IRA (13)
Job creations (871)
Job search strategy (139)
JPM (41)
Kidney cancer (13)
Kidney disease (126)
Labor market (46)
Layoffs (280)
Leadership (22)
Legal (1406)
Licensing (99)
Liver cancer (54)
Longevity (39)
Lung cancer (701)
Lung diease (21)
Lymphoma (369)
Machine learning (37)
Management (8)
Manufacturing (713)
Marketing (25)
MASH (189)
Medical affairs (4)
Medical device (2759)
Medtech (2814)
Melanoma (110)
Mergers & acquisitions (6990)
Metabolic disorders (1117)
Middle East (1)
mRNA (230)
Multiple sclerosis (162)
Multispecific (6)
NASH (14)
Netherlands (19)
Neurodegenerative disease (433)
Neuropsychiatric disorders (105)
Neuroscience (2778)
Neurotech (2)
NextGen: Class of 2026 (2040)
Non-profit (891)
Now hiring (50)
Obesity (496)
Opinion (161)
Ovarian cancer (232)
Pain (175)
Pancreatic cancer (312)
Parkinson's disease (366)
Partnered (19)
Patents (512)
Patient advocacy (7)
Patient recruitment (682)
Patient selection (93)
Peanut (55)
People (27975)
Peptides (33)
Pharmaceutical (31)
Pharmacy benefit managers (9)
Phase 1 (16516)
Phase 2 (21706)
Phase 3 (13730)
Pipeline (9241)
Policy (114)
Postmarket research (853)
Preclinical (6977)
Press Release (30)
Prostate cancer (247)
Psychedelics (89)
Radioligand (3)
Radiopharmaceuticals (342)
Rare diseases (1133)
Real estate (1461)
Recruiting (12)
Regenerative medicine (24)
Regulatory (11460)
Reports (33)
Research institute (1008)
Resumes & cover letters (20)
Rett syndrome (51)
RNA editing (38)
RSV (26)
Schizophrenia (175)
Series A (295)
Series B (198)
Series C (1)
Service/supplier (1)
Sickle cell disease (110)
Special edition (24)
Spinal muscular atrophy (131)
Sponsored (22)
Startups (2057)
State (1)
Stem cells (7)
Stomach cancer (7)
Substance use disorders (20)
Supply chain (49)
Switzerland (15)
Tariffs (20)
The Weekly (98)
Vaccines (472)
Venture capital (120)
Weight loss (263)
Wet AMD (6)
Women's health (63)
Women in leadership (1)
Worklife (4)
Date
Today (1)
Last 7 days (396)
Last 30 days (2069)
Last 365 days (18396)
2026 (16919)
2025 (18094)
2024 (20467)
2023 (22412)
2022 (26810)
2021 (27802)
2020 (23355)
2019 (16222)
2018 (11735)
2017 (13743)
2016 (11838)
2015 (14348)
2014 (10392)
2013 (7483)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (160)
Alabama (86)
Alaska (2)
Arizona (108)
Arkansas (6)
Asia (19316)
Australia (3328)
California (10483)
Canada (2597)
China (1383)
Colorado (397)
Connecticut (395)
Delaware (364)
Europe (41379)
Florida (1380)
Georgia (289)
Hawaii (3)
Idaho (18)
Illinois (656)
India (78)
Indiana (246)
Iowa (13)
Japan (408)
Kansas (93)
Kentucky (13)
Louisiana (18)
Maine (14)
Maryland (1072)
Massachusetts (8370)
Michigan (143)
Minnesota (362)
Mississippi (4)
Missouri (41)
Montana (17)
Nebraska (6)
Nevada (71)
New Hampshire (22)
New Jersey (2357)
New Mexico (14)
New York (2545)
North Carolina (1214)
North Dakota (9)
Northern California (5449)
Ohio (254)
Oklahoma (12)
Oregon (28)
Pennsylvania (1899)
Puerto Rico (12)
Rhode Island (31)
South America (217)
South Carolina (20)
Southern California (4257)
Tennessee (72)
Texas (1505)
United States (34544)
Utah (145)
Virginia (212)
Washington D.C. (37)
Washington State (850)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
296,724 Results for "acelink therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study
AceLink is advancing a small-molecule treatment option for Fabry disease that could provide a more convenient alternative to the current enzyme replacement therapy standard.
February 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients
August 15, 2025
·
2 min read
Biotech Bay
AceLink Therapeutics to Present at World Orphan Drug Congress USA
AceLink Therapeutics, Inc. today announced that Jerry Shen, Ph.D., Chief Executive Officer and Co-Founder of AceLink Therapeutics, will present at the World Orphan Drug Congress Conference.
May 17, 2023
·
1 min read
Drug Development
AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers
AceLink Therapeutics, Inc. today announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.
February 26, 2024
·
3 min read
Business
AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer
AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).
May 8, 2023
·
4 min read
Drug Development
AceLink Presents Preclinical Data on AL00804 at WORLD Symposium
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today presented data on the development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor, to treat Gaucher disease and other neuronopathic glycosphingolipid (GSL) storage diseases.
February 23, 2023
·
3 min read
Drug Development
AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease
AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.
October 31, 2023
·
3 min read
Drug Development
AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease
AceLink Therapeutics, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of its lead program, AL1211.
June 21, 2023
·
5 min read
Press Releases
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
February 9, 2025
·
3 min read
Drug Development
AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
AceLink Therapeutics, Inc. announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics, pharmacodynamics and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.
August 10, 2023
·
3 min read
1 of 29,673
Next